| Literature DB >> 32552178 |
Mohammad Taghi Beigmohammadi1, Behnaz Jahanbin1, Masoomeh Safaei1, Laya Amoozadeh1, Meysam Khoshavi1, Vahid Mehrtash1, Bita Jafarzadeh1, Alireza Abdollahi1.
Abstract
Background. A novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been affecting almost all nations around the world. Most infected patients who have been admitted to intensive care units show SARS signs. In this study, we aimed to achieve a better understanding of pathological alterations that take place during the novel coronavirus infection in most presumed affected organs. Methods. We performed postmortem core needle biopsies from lung, heart, and liver on 7 deceased patients who had died of coronavirus disease 2019. Prepared tissue sections were observed by 2 expert pathologists. Results. Diffuse alveolar damage was the main pathologic finding in the lung tissue samples. Patients with hospitalization durations of more than 10 days showed evidence of organization. Multinucleated cells in alveolar spaces and alveolar walls, atypical enlarged cells, accumulation of macrophages in alveolar spaces, and congestion of vascular channels were the other histopathologic alteration of the lung. None of our heart biopsy samples met the criteria for myocarditis. Liver biopsies showed congestion, micro- and macro-vesicular changes, and minimal to mild portal inflammation, in the majority of cases. Conclusions. Similar to the previous coronavirus infection in 2003, the main pathologic finding in the lung was diffuse alveolar damage with a pattern of organization in prolonged cases. The SARS-CoV-2 infection does not cause myocarditis, and the ischemia of myocardium is the most probable justification of the observed pathologic changes in the heart. Liver tissue sections mostly showed nonspecific findings; however, ischemia of the liver can be identified in some cases.Entities:
Keywords: COVID-19; lung; pathology; postmortem examination; severe acute respiratory syndrome coronavirus 2
Mesh:
Year: 2020 PMID: 32552178 PMCID: PMC8041443 DOI: 10.1177/1066896920935195
Source DB: PubMed Journal: Int J Surg Pathol ISSN: 1066-8969 Impact factor: 1.271
Clinical Features of Deceased COVID-19 Patients.
| Patient | Age/sex (years) | Clinical presentation at admission | Past medical history | Drug history | Medications used for COVID-19 | Duration of hospital stay (days) | Duration of intubation (days) |
|---|---|---|---|---|---|---|---|
| 1 | Male/58 | Fever, dyspnea, nausea, and vomiting | HTN | Losartan, aspirin | HCQ, atazanavir | 7 | 4 |
| 2 | Female/84 | Fever, dyspnea, myalgia | HTN | Amlodipine, aspirin, citalopram | HCQ, LPV/r[ | 3 | 3 |
| 3 | Female/72 | Fever, headache, nausea, and vomiting | Rheumatoid arthritis | Sulfasalazine, prednisolone, MTX | HCQ, levofloxacin | 15 | 6 |
| 4 | Male/72 | Fever, dyspnea, diarrhea | HTN, DM | Insulin[ | HCQ, oseltamivir, azatanavir, levofloxacin | 4 | 2 |
| 5 | Male/68 | Fever, dyspnea | HTN, valvular heart disease | Losartan, propranolol | HCQ, oseltamivir | 19[ | 8 |
| 6 | Male/46 | Fever, dyspnea, myalgia, and sore throat | PUD | Chlordiazepoxide/clidinium | HCQ, remdesivir, naproxen, cefepime | 16 | 10 |
| 7 | Male/75 | Fever, dyspnea, anorexia | None | None | HCQ, oseltamivir | 6 | 5 |
Abbreviations: HTN, hypertension; HCQ, hydroxycholorquine; LPV/r, lopinavir/ritonavir (Kaletra); MTX, methotrexate; DM, diabetes mellitus; PUD, peptic ulcer disease.
Tamiflu.
NovoRapid and Lantus.
This patient was admitted to hospital due to endocarditis and had undergone heart valve replacement surgery. Respiratory symptoms revealed about 11 days before expiration.
Pulmonary Pathologic Findings of Deceased COVID-19 Patients.
| Patient | |||||||
|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | |
| Hyaline membrane formation | Present | Present | NI | Present | Present | NI | Present |
| Edema | Present | Present | Present | Present | Present | Present | Present |
| Fibrin exudation | NI | Present | Present | NI | Present | Present | Present |
| Multinucleation | Present | Present | Present | NI | Present | Present | NI |
| Inflammation intensity | Severe in 1 out of 4 cores but mild in other cores | Mild | Severe | Mild and focal | Moderate | Severe | Severe |
| Inflammation site | Alveolar walls | Alveolar walls | Alveolar spaces | Alveolar wall | Alveolar walls and alveolar spaces | Alveolar space and alveolar walls | Alveolar spaces and alveolar walls |
| Predominant type of inflammatory cells | Lymphocytes and plasma cells with few PMNs | Lymphocytes with occasional PMNs | PMNs and few lymphocytes | Lymphocyte and rare PMNs | Lymphocytes and few PMNs | PMNs and lypmhocytes | PMNs and lymphocytes |
| Pneumocyte type II hyperplasia | Present | NI | Present | NI | Present | Present | Present |
| Atypical enlarged cells | Present | Present | Present | Present | Present | Present | Present |
| Acute pneumonia pattern | NI | NI | Present | NI | NI | Present | Present with necrosis |
| Organization | NI | NI | Present | NI | Present | Present | NI |
| Accumulation of macrophages in alveolar spaces | Present | Present | Present | NI | Present (hemosiderin-laden macrophages are also seen) | Present | NI |
| Fresh hemorrhage | Present | NI | NI | NI | NI | Present | NI |
| Vessels | Fibrinoid material deposition in vessel walls | Fibrinoid material deposition in vessel walls | No obvious pathological finding | No obvious pathological finding | No obvious pathological finding | No obvious pathological finding | Fibrinoid material deposition in vessel walls |
| Squamous metaplasia | No obvious bronchioles | NI | NI | No obvious bronchioles | Present, associated with bronchiolitis | No obvious bronchioles | NI |
Abbreviation: NI, not identified; PMN, polymorphonuclear neutrophils.
Figure 1.Pathologic findings of lung tissue of case 1. (A) Hyaline membrane formation; (B) intra-alveolar atypical enlarged cells; (C) multinucleated cells; (D) deposition of fibrinoid material in vessel walls.
Figure 2.Pathologic findings of lung tissue of case 7. (A) Hyaline membrane formation; (B, C) necrosis and acute inflammatory reaction; (D) squamous metaplasia of bronchiole.
Figure 3.Pathologic findings of lung tissue of case 3. (A, B) Proliferation of fibroblasts (organizing diffuse alveolar damage); (C) acute pneumonia; (D) enlarged atypical cell.
Figure 4.Lung tissue samples immunohistochemistry study results. (A) CD3 stained major proportion of lymphocytes; (B) CD20 stained few lymphocytes; (C) CD68, a histiocytic marker, stained major population of intra-alveolar cells; (D) CD68 stained some multinucleated cells; (E) some multinucleated cells did not stain with LCA; (F) large atypical cells (arrow) did not stain with LCA; (G, H) large atypical cells stained with CKAE1/AE3 and TTF1.
Heart Pathologic Findings of Deceased COVID-19 Patients.
| Patient | |||||||
|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | |
| Interstitial inflammation | Present | No heart tissue | Present | No heart tissue | Present | Not identified | present |
| Intensity of inflammation | Focal (<4/mm2) | — | Mild to moderate (>20/mm2) | — | Severe (>34/mm2) | N/A | Mild to moderate (20/mm2) |
| Myocyte necrosis | Not seen | — | Not seen | — | present | N/A | |
| Vasculitis | Not seen | — | Not seen | — | Not seen | N/A | |
| LCA positive cells | N/A | — | >23/mm2 | — | >34/mm2 | N/A | >24/mm2 |
| CD3 positive cells | N/A | — | Negative | — | <10/mm2 | N/A | <4/mm2 |
| CD68 positive cells | N/A | — | >23/mm2 | — | >24/mm2 | N/A | >20/mm2 |
Abbreviations: N/A, not applicable; LCA, leukocyte common antigen.
Figure 5.Pathologic findings of heart tissue biopsy of case 5.(A) Interstitial inflammatory infiltrate with ischemic necrosis; (B) immunohistochemical (IHC) staining for LCA; (C) IHC staining for CD68; (D) IHC staining for CD3.
Liver Pathologic Findings of Deceased COVID-19 Patients.
| Patient | Number of portal tracts in biopsy | Portal inflammation | Interface hepatitis | Confluent necrosis | Focal lytic necrosis, apoptosis, and focal inflammation | Trichrome stain | Reticulin stain | Congestion | Other findings |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 15 | Mild | Mild | Absent | One focus or less per 10× objective | Unremarkable | Focal regeneration | Mild | Mild macrovesicular steatosis involves about 5% of lobular area, and mild microvesicular change. |
| 2 | 13 | Minimal | Absent | Absent | One focus or less per 10× objective | Unremarkable | Unremarkable | Severe | Mild macrovesicular steatosis involves about 30% of lobular area, mild microvesicular, and mild ballooning degeneration. |
| 3 | 4 | Mild | Mild | Absent | One focus or less per 10× objective | Mild fibrosis | Focal regeneration | Moderate | Minimal macrovesicular steatosis involves less than 5% of lobular area and scattered bile plugs. |
| 4 | 15 | Mild | Absent | Absent (but Focal hepatocyte drop out is seen) | One focus or less per 10× objective | Unremarkable | Unremarkable | Mild | Minimal macrovesicular steatosis involves about 5% of lobular area and mild microvesicular changes. |
| 5 | 13 | Mild | Mild | Absent | One focus or less per 10× objective | Unremarkable | Unremarkable | Moderate | Mild ballooning degeneration and focal bile plug |
| 6 | 27 | Minimal | Absent | Absent | One focus or less per 10× objective | Unremarkable | Focal regeneration | Moderate to severe | Mild macrovesicular steatosis involves about 30% of lobular area, mild microvesicular changes, and mild ballooning degeneration. |
| 7 | 15 | Mild | Mild | Present (focal confluent necrosis in acinar zone 3 and 2 is seen) | One focus or less per 10× objective | Unremarkable | Focal regeneration | Moderate | Minimal macrovesicular steatosis involves about 5% of lobular area, moderate microvesicular changes, and mild ballooning degeneration. |
Figure 6.Pathologic findings of liver tissue samples. (A) Focal confluent necrosis (case 7); (B) moderate microvesicular changes (case 5); (C) mild portal tract mixed inflammation with focal interface hepatitis (case 1); (D) mild steatosis (predominantly macrovesicular) involves about 30% of lobular area admixed with mild microvesicular change (case 2).